Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia-Reference-Cited by-同舟云学术

Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia

Published:2017-07-28 Issue:35 Volume:8 Page:57948-57963
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

McArthur Kate¹²,D’Cruz Akshay A.³⁴,Segal David¹²,Lackovic Kurt¹²,Wilks Andrew F.¹,O’Donnell Joanne A.¹²⁵,Nowell Cameron J.⁶,Gerlic Motti¹⁷,Huang David C.S.¹²,Burns Christopher J.¹²⁸,Croker Ben A.¹²³⁴

Affiliation:

1. Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia

2. Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia

3. Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA

4. Department of Pediatrics, Harvard Medical School, Boston, MA, USA

5. Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA

6. Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia

7. Department of Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel

8. School of Chemistry, Bio21, The University of Melbourne, Melbourne, VIC, Australia

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NET formation is a default epigenetic program controlled by PAD4 in apoptotic neutrophils;Science Advances;2023-12-22

2. Immunotherapy and Radiotherapy for Older Cancer Patients during the COVID-19 Era: Proposed Paradigm by the International Geriatric Radiotherapy Group;Gerontology;2021

3. Learning important features from multi-view data to predict drug side effects;Journal of Cheminformatics;2019-12

4. Polo-like kinases and acute leukemia;Oncogene;2018-08-13